PASADENA, CA--(Marketwire - February 10, 2011) - Sanguine Corp. (OTCBB: SGUI) is pleased to announce that it has appointed Frank Marra as the President of the Company. Mr. Marra has spent the past two years serving as the President of the Company's wholly-owned subsidiary, Sanguine Lifesciences Corp.
Prior to joining the Sanguine team, Mr. Marra spent the past 20 years serving as a Management Consultant to numerous public and private companies. He has an extensive background in both biotechnology and small company finance. Mr. Marra has served as the CEO/President to a number of emerging growth companies. Prior to heading Sanguine Lifesciences, Mr. Marra served as CEO of Rheologics, Inc. of Exton, PA, a medical device manufacturer of and developer of the RHEOLOG®, the world's first whole blood viscometer. In addition, Mr. Marra has been a senior consultant to over fifty healthcare related companies. Mr. Marra is also a founding member and principal of two private investment firms, Stonebridge Ross and LKB Partners, LLC.
Dr. Thomas Drees, CEO and Founder of Sanguine, said, "Frank is an excellent choice to lead our Company at this time. He has a remarkable knowledge of the biotech world and unprecedented experience in growing small companies. We strongly support his hiring and look forward to working with him to lead us in the future."
Mr. Marra stated, "I have spent a considerable amount of time and effort over the past 24 months helping Sanguine position itself for the future. I am honored that I now have the opportunity to serve as President to advance Company to where it deserves to be. We believe that we have an exciting number of high potential opportunities in front of us and I am looking forward to working with our team to make the most out of each and every one."
About Sanguine Corp:
Sanguine Corporation is keenly focused on pioneering the development and commercialization of innovative perfluorocarbon-based therapies and medical devices. Its lead product, PHER-02, is an intravenous perfluorocarbon emulsion that is highly efficient at dissolving and delivering oxygen to tissues. Such properties make PHER-02 an ideal product for the treatment of a myriad of medical conditions with high morbidity and/or mortality directly resulting from a lack of oxygen at the cellular level. Sanguine's philosophy is to develop products that have a sound scientific basis, a demonstrated proof of concept and adhere to the highest industry standards of product development.
For information related to the Sanguine Corp., contact Investor Relations: Michael Dancy, 801-746-3570, email: medancy@dancycorp.com.
Cautionary Note Regarding Forward-Looking Statements:
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
